FDA Eyes Alpharma's Embeda Over Abuse Effects

Law360, New York (November 12, 2008, 12:00 AM EST) -- U.S. Food and Drug Administration officials are concerned that design features meant to cut down on abuse of Alpharma Inc.'s Embeda aren't enough to prevent addicts from misusing the potent painkiller.

Alpharma, which is currently seeking the agency's stamp of approval to market the extended-release drug for moderate to severe chronic pain, claims that a special abuse-deterrent formulation makes it more difficult for drug addicts to misuse the morphine-based medication.

But in prepared documents issued ahead of a joint meeting on Friday of the FDA's anesthetic...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.